FHTX · Foghorn Therapeutics, Inc.

2.02

USD

-0.90 (-30.822%)

02/10/2026 04:00:00 PM

Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

US$119.96M

0.00

EV/EBITDA

N/A

DIV Yield

0%

Payout Ratio

0%

MQV Rating

5Very Weak

As at 02/10/2026 04:00:00 PM

Price Chart

Description

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Watertown, MA.

All-Companies
All-Consensus
Big Candle (Realtime)
Engulfing Bearish
Engulfing Bullish
HALO All
HALO Consensus Value
HALO Earnings Momentum
Hammer Bearish
Hammer Bullish
Near Support
Near Support (Realtime)
Volume Spike

Key Fundamentals

EPS 3 yr Growth

-54.90%

EBITDA Margin

-254.90%

Operating Cashflow

-$86m

Free Cash Flow Return

0.00%

ROIC

0.00%

Interest Coverage

N/A

Quick Ratio

2.70

Performance

52 weeks range

Low 1.79 - 7.61

Trade Value (12mth)

US$292,581.00

1 week

-15.46%

1 month

-43.73%

YTD

-32.56%

1 year

-27.98%

All time high

28.26

Additional Data

Shares Outstanding (Fully Diluted)

71m

HALO Sector

Healthcare

Next Company Report Date

11-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

Consensus

Unlock full consensus

Consensus score

/10

Recommendation

Buy

Target price

Deviation

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

Valuation

Unlock full dataset

Value

Consensus

Yield

News & Announcements

Date	Event
01 October 26EDG
06 August 26EDG
06 August 26EDG
06 August 26EDG
06 August 26EDG

Key Stakeholders

Name	Title
Flagship Pioneering Inc	Private Company
Deerfield Management Co. LP (Private Equity)	Subsidiary
Eli Lilly & Co.	Public Company
Cigall Kadoch	Individual
Euclidean Capital LLC	Private Company